Category Archives: Global

Unmet Need in the Migraine Space?

Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Also posted in FDA, Marketing, Regulatory, Strategy, Technology | Tagged , , , , | 2 Comments

Roche Ups the Stakes on Personalized Medicine

By Patricia Van Arnum, Pharmaceutical Technology. Personalized medicine, which targets individualized treatment and care based on personal and genetic variations, holds much promise for the pharmaceutical industry. Several pharmaceutical majors continue to invest in this emerging field as evident by Roche’s $5.7-billion bid last week for Illumina, a provider of gene-sequencing tools and related analytics.
Also posted in Biotech, Europe, Guest Blog | Tagged , , | Leave a comment

Pharma: Get Ready for the New Supply Chains

New pharma supply chains, where chill control and traceability challenges will be far more critical, will emerge over the next decade, So it’s time, argues Julian Mosquera, for the industry to upgrade its capabilities. The pharmaceuticals industry is undergoing major disruption and every comparative benchmark indicates that the sector needs to make a step change in [...]
Also posted in Guest Blog, Safety, Supply Chain | Tagged , , | 1 Comment

Arise Sir Andrew (Witty)

Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Also posted in Op-Ed, leadership | Tagged , , , | Leave a comment

Lilly's Decentralized Global Launch Strategy

Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
Also posted in Market Access, Strategy, leadership | Tagged , | Leave a comment